Analysts expect Esperion Therapeutics, Inc. (NASDAQ:ESPR) to report $-1.80 EPS on February, 28.They anticipate $0.51 EPS change or 39.53% from last quarter’s $-1.29 EPS. After having $-1.86 EPS previously, Esperion Therapeutics, Inc.’s analysts see -3.23% EPS growth. The stock increased 0.46% or $0.34 during the last trading session, reaching $74.92. About 371,409 shares traded. Esperion Therapeutics, Inc. (NASDAQ:ESPR) has risen 133.75% since February 19, 2017 and is uptrending. It has outperformed by 117.05% the S&P500.
Among 11 analysts covering Helix Energy Solutions (NYSE:HLX), 7 have Buy rating, 2 Sell and 2 Hold. Therefore 64% are positive. Helix Energy Solutions had 28 analyst reports since July 22, 2015 according to SRatingsIntel. The company was initiated on Thursday, October 6 by DA Davidson. Cowen & Co maintained Helix Energy Solutions Group, Inc. (NYSE:HLX) rating on Wednesday, August 30. Cowen & Co has “Buy” rating and $9.0 target. As per Friday, October 23, the company rating was downgraded by TheStreet. On Thursday, January 21 the stock rating was upgraded by Stephens to “Overweight”. The rating was upgraded by Credit Suisse on Tuesday, April 12 to “Outperform”. The stock of Helix Energy Solutions Group, Inc. (NYSE:HLX) has “Hold” rating given on Friday, December 22 by Piper Jaffray. As per Wednesday, September 27, the company rating was downgraded by PiperJaffray. The firm earned “Buy” rating on Thursday, January 11 by Cowen & Co. The firm has “Market Perform” rating given on Monday, September 21 by Cowen & Co. The stock of Helix Energy Solutions Group, Inc. (NYSE:HLX) has “Overweight” rating given on Tuesday, April 19 by Morgan Stanley. See Helix Energy Solutions Group, Inc. (NYSE:HLX) latest ratings:
16/01/2018 Broker: Bank of America Rating: Sell New Target: $7.5 Downgrade
11/01/2018 Broker: Cowen & Co Rating: Buy New Target: $10.0 Maintain
22/12/2017 Broker: Piper Jaffray Rating: Hold New Target: $7.25 Maintain
06/10/2017 Broker: Cowen & Co Rating: Buy New Target: $9.0 Maintain
27/09/2017 Broker: PiperJaffray Old Rating: Overweight New Rating: Neutral Downgrade
05/09/2017 Broker: Bank of America Rating: Neutral New Target: $7 Initiates Coverage On
30/08/2017 Broker: Cowen & Co Rating: Buy New Target: $9.0 Maintain
Helix Energy Solutions Group, Inc., together with its subsidiaries, provides specialty services to the offshore energy industry primarily in the Gulf of Mexico, North Sea, the Asia Pacific, and West Africa regions. The company has market cap of $1.03 billion. It operates through three divisions: Well Intervention, Robotics, and Production Facilities. It currently has negative earnings. The firm engineers, manages, and conducts well construction, intervention, and abandonment activities in water depths ranging from 200 to 10,000 feet; and operates remotely operated vehicles , trenchers, and ROVDrills for offshore construction, maintenance, and well intervention services.
It closed at $6.96 lastly. It is down 16.48% since February 19, 2017 and is downtrending. It has underperformed by 33.18% the S&P500.
Among 18 analysts covering Esperion Therapeutics (NASDAQ:ESPR), 11 have Buy rating, 0 Sell and 7 Hold. Therefore 61% are positive. Esperion Therapeutics had 53 analyst reports since July 28, 2015 according to SRatingsIntel. On Thursday, June 30 the stock rating was maintained by Needham with “Buy”. The rating was maintained by JMP Securities on Wednesday, March 9 with “Market Outperform”. Stifel Nicolaus maintained the shares of ESPR in report on Monday, January 15 with “Buy” rating. Needham upgraded the stock to “Buy” rating in Monday, August 10 report. Chardan Capital Markets maintained Esperion Therapeutics, Inc. (NASDAQ:ESPR) rating on Monday, July 27. Chardan Capital Markets has “Sell” rating and $40 target. The stock of Esperion Therapeutics, Inc. (NASDAQ:ESPR) earned “Sell” rating by Chardan Capital Markets on Friday, August 7. The firm earned “Buy” rating on Thursday, December 14 by Needham. Stifel Nicolaus maintained the shares of ESPR in report on Monday, June 26 with “Buy” rating. The stock has “Buy” rating by Deutsche Bank on Wednesday, August 9. The rating was maintained by Chardan Capital Markets with “Sell” on Monday, August 31.
Esperion Therapeutics, Inc., a lipid management company, focuses on developing and commercializing oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol . The company has market cap of $1.96 billion. The Company’s lead product candidate is Bempedoic acid, an inhibitor of ATP-citrate lyase that reduces cholesterol biosynthesis that is in Phase III long-term safety and tolerability study. It currently has negative earnings.
Investors sentiment increased to 1.67 in Q3 2017. Its up 0.45, from 1.22 in 2017Q2. It increased, as 11 investors sold Esperion Therapeutics, Inc. shares while 34 reduced holdings. 30 funds opened positions while 45 raised stakes. 22.73 million shares or 17.55% more from 19.33 million shares in 2017Q2 were reported. Emory University reported 33,975 shares. Nationwide Fund Advisors invested in 22,952 shares or 0% of the stock. Fmr Limited Liability Company invested in 0.01% or 1.34M shares. 7,673 are owned by Voya Investment Mgmt Ltd Liability Company. Nj State Employees Deferred Compensation Plan owns 13,125 shares or 0.12% of their US portfolio. Massachusetts-based Geode Cap Management Limited Liability Company has invested 0% in Esperion Therapeutics, Inc. (NASDAQ:ESPR). American holds 0% or 11,257 shares. Millennium Management Limited holds 0% of its portfolio in Esperion Therapeutics, Inc. (NASDAQ:ESPR) for 33,367 shares. Pinnacle has 717,813 shares. Pictet Asset Management Ltd holds 306,455 shares or 0.04% of its portfolio. Sabby Mngmt Ltd Limited Liability Company invested 0.27% of its portfolio in Esperion Therapeutics, Inc. (NASDAQ:ESPR). St Johns Invest reported 260 shares. The Ohio-based Victory Mgmt Incorporated has invested 0% in Esperion Therapeutics, Inc. (NASDAQ:ESPR). Aqr Mngmt Limited Co invested in 103,726 shares. C Group A S invested in 5,012 shares or 0% of the stock.